Investegate |Oxford BioDynamics Announcements | Oxford BioDynamics: Initial assessment of EpiSwitch assay in ALS trial
Investegate announcements from Oxford BioDynamics, Initial assessment of EpiSwitch assay in ALS trial
Source: investegate.co.uk
Stay updated with breaking news from Jon Burrows. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Oxford BioDynamics, Initial assessment of EpiSwitch assay in ALS trial
Investegate announcements from Oxford BioDynamics, Exercise period extension - existing share options
Dr. Steven Mamus, Medical Director of Oncology/Hematology, Cancer Center of Sarasota (FL, US), to present how OBD's EpiSwitch CIRT is transforming the way Immune Checkpoint Inhibitor (ICI) therapy
Investegate announcements from Oxford BioDynamics, Director/PDMR Shareholding
Investegate announcements from ,